Dynein axonemal heavy chain 7 (DNAH7)
Homo sapiens — UniProt Q8WXX0
Gene: DNAH7Homo sapiensSwissProt reviewed
Data last refreshed: (UniProt release unknown)
Key facts
Dynein axonemal heavy chain 7 (DNAH7) is a protein from Homo sapiens identified by UniProt accession Q8WXX0, 4024 residues long. MolForge cross-references it against 0 known binders and 53 disease associations.
- UniProt accession: Q8WXX0; gene symbol DNAH7.
- Organism: Homo sapiens.
- Length: 4024 amino acids.
- Top disease associations (Open Targets): primary ciliary dyskinesia, Abnormal muscle tone and Abnormal basal ganglia morphology.
- 3D structure: AlphaFold model available.
Target properties
| Protein name | Dynein axonemal heavy chain 7 |
|---|---|
| UniProt accession | Q8WXX0 |
| Gene | DNAH7 |
| Organism | Homo sapiens |
| Length | 4024 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | — |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|---|
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (53)
Diseases linked to this target (Open Targets).
- primary ciliary dyskinesia · score 0.42
- Abnormal muscle tone · score 0.33
- Abnormal basal ganglia morphology · score 0.33
- basal ganglia disease · score 0.33
- Seizure · score 0.33
- Hypoplasia of the corpus callosum · score 0.33
- Dyspnea · score 0.33
- cortical surface area measurement · score 0.30
- heel bone mineral density · score 0.29
- monocyte count · score 0.27
3D Structure (10)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|---|---|---|---|
| AF-Q8WXX0-F15 | alphafold | PREDICTED | 89.71 | — |
| AF-Q8WXX0-F6 | alphafold | PREDICTED | 89.06 | — |
| AF-Q8WXX0-F5 | alphafold | PREDICTED | 87.96 | — |
| AF-Q8WXX0-F7 | alphafold | PREDICTED | 87.39 | — |
| AF-Q8WXX0-F2 | alphafold | PREDICTED | 87.30 | — |
| AF-Q8WXX0-F3 | alphafold | PREDICTED | 87.24 | — |
| AF-Q8WXX0-F4 | alphafold | PREDICTED | 87.20 | — |
| AF-Q8WXX0-F11 | alphafold | PREDICTED | 86.68 | — |
Experimental structures are not indexed in MolForge yet — search RCSB PDB for Q8WXX0.
Amino-acid sequence (4024 residues)
MSSEQDKSAS KEKSKKPVRF LPQLSMEKLA SKEKFKAPAR ALPQLSMVST KPHWQQAAPS FHLSVKQDDE SPEPFSVKNE QSHAEYMERF GKKGKLPHQV DDSYVGPSTS KSKGKSPHKE RENFRSTLVN VIMQQDADLD SAVPDGSTIP KPTASAIEKD ILRYYYYIHH GIDTDHVAPM EDSWLEHVLD LVPQHLKVFT DSIVTLSDEM REDYLLSVRK SIVDFVLKDP REKGDDKKTD ELPAHRAEME ILPKPWRKSF LAASSYIRDH LNAMNPTMLA VLDLWHTNFK KLRLVDIKEF HNCQDALELS SFQNIIMRHM DSAKETLLKM WFPEVQNIYY QGNKKKQLPT GDSSAKLESF FNCAAALMTL QLQDLTLVSM QDFTDLIAQP PDSVRAFEHP GFIMRLILDN DTIKFEPELS DYIDIFLNVY DVMIKAVSFV PRVETKLYSK WESKSKPTTL KPIILNEIVD AHKEKIKEVI MKESVAPTEH LRLYDKYDFL ITRKAERDVD NFLAENHSYE KIIDEICKYQ KLIEEIQYTS IKTIRLGMFE MHCEELIRAL VKRADIICGK LLAKMFRDHQ EVNTRLCDEF ERIAEKALST PPNTAELMEM KAYIQKVEVT DMIELEQRLV DSKNCLAFLI EYVNFSPADM RLNNSVFQWY GRMGEIFEEH RKIIKEKIEQ YQEGLKLRCE RFVEELESYA KQSEEFYSFG DLQDVQRYLK KAQILNGKLD LAADKIEQFN AEEEAFGWLP SVYPQRKKIQ DGLNPYLRLY ETAVEFSSNY RAWTEGPYHK VNPDQVEADI GNYWRGLYKL EKTFHDSPYA LAMTKKVRSK VEDFKQHIPL IQVICNPGLR PRHWEAMSAI VGYPLQPSDD STVSSFLDMN LEPYIDRFEG ISEAASKEYS LEKAMEKMIT EWDAVEFVIH SYRETGTFIL ASVDEIQMLL DDHIIKTQTM RGSPFIKPYE KQMREWEGKL LLLQEILDEW LKVQATWLYL EPIFSSPDIM SQMPEEGRRF TAVDKTWRDI MRSVMQDKHV LTVVTIDRML ERLKKSNELL ELILKGLNEY LEKKRLFFPR FFFLSNDELL EILSETKDPT RVQPHLKKCF EGIAKVEFTE TLDITHMKSS EGEVVELIEI ISTAKARGQV EKWLVELERV MINSIHKVTG DATFAYTKYE RINWVRDWPG QTVLCVSQIF WTKEVQTAIP MGIKALEQYL KTCNRQIDDI VTLVRGKLSM QNRVTLGALV VLDVHARDVL SSLVKKNISD DSDFEWLSQL RYYWQENHLE TKMINAGLRY GYEYLGNSPR LVITPLTDRC YRTLFGALHL HLGGAPEGPA GTGKTETTKD LAKAVAKQCV VFNCSDGLDY LALGKFFKGL LSCGAWACFD EFNRIDLEVL SVVAQQILTI QRGINAGADI LMFEGTELKL DPTCAVFITM NPGYAGRSEL PDNLKALFRT VAMMVPDYAM IAEIVLYSCG FVTARPLSVK IVATYRLCSE QLSSQHHYDY GMRAVKSVLT AAGNLKLKYP NENEEILLLR SIIDVNLPKF LSHDLPLFEG ITSDLFPGVK LPKPDYNDLL AAIKDNCASM NLQMTAFFSE KILQVYEMMI VRHGFMIVGE PFGGKTSAYR VLAGALNDIC EKGLMEENKV QITVLNPKSV TMGQLYGQFD SVSHEWSDGV LAVSFRAFAS SVTPDRKWLI FDGPVDAVWI ENMNTVLDDN KKLCLMSGEI IQMSPQMNLI FEPMDLEVAS PATVSRCGMI YMEPHMLGWR PLMLSWVNLL PASVSVIQKE FIMGLFDRMV PVSVEFIRKH TKELSPTSDT NLVRSLMNLI DCFMDDFADE VKLKERNDRE TYSLLEGIFL FSLIWSVGAS CTDDDRLKFN KILRELMESP ISDRTRNTFK LQSGTEQTSS KALTVPFPEK GTIYDYQFVT EGIGKWEPWI KKLKEAPPIP KDVMFNEIIV PTLDTIRYSA LMELLTTHQK PSIFVGPTGT GKSVYITNFL LNQLNKEIYK PLLINFSAQT TAAQTQNIVM SKLDKRRKGV FGPPLGKRMV VFVDDVNMPA REVYGAQPPI ELLRQWLDHW NWYDLKDCSM IKLVDIQIMC AMGPPGGGRN PVTPRYMRHF NIITINEFSD KSMYTIFSRI LTWHLEICYK FPDEFLDLTT QIVNGTMTLY KEAMKNLLPT PAKSHYLFNL RDFSRVIQGV CLSRPETTET TEVIKRLWVH EVLRVYYDRL LDNTDRSWLI NYIQEILRNY MYEDFHELFQ RLDFDNDGMV EADDLRSLMF CDFHDPKRED TNYREIADVD NLRMIVEIHL EEYNNISKKP MNLVLFRFAI EHISRISRIL KQPRSHALLV GVGGSGRQSV TRLAAHMADY SVFQVEISKG YDTTEWHEDL KVILRKCAEG EMQGVFLFTD TQIKEESFLE DVSNLLNAGE IPNLFALDEK QEICDKMRQL DRQRDKTKQT DGSPIALFNM FIDHCRSQLH VVLAMSPIGD AFRNRLRKFP ALVNCCTIDW FQSWPEDALQ AVASRFLEEI EMSEEIRDGC IDMCKSFHTS TIDLSKSFFV ELQRYNYVTP TSYLELISTF KLLLEKKRSE VMKMKKRYEV GLEKLDSASS QVATMQMELE ALHPQLKVAS KEVDEMMIMI EKESVEVAKT EKIVKADETI ANEQAMASKA IKDECDADLA GALPILESAL AALDTLTAQD ITVVKSMKSP PAGVKLVMEA ICILKGIKAD KIPDPTGSGK KIEDFWGPAK RLLGDMRFLQ SLHEYDKDNI PPAYMNIIRK NYIPNPDFVP EKIRNASTAA EGLCKWVIAM DSYDKVAKIV APKKIKLAAA EGELKIAMDG LRKKQAALKE VQDKLARLQD TLELNKQKKA DLENQVDLCS KKLERAEQLI GGLGGEKTRW SHTALELGQL YINLTGDILI SSGVVAYLGA FTSTYRQNQT KEWTTLCKGR DIPCSDDCSL MGTLGEAVTI RTWNIAGLPS DSFSIDNGII IMNARRWPLM IDPQSQANKW IKNMEKANSL YVIKLSEPDY VRTLENCIQF GTPVLLENVG EELDPILEPL LLKQTFKQGG STCIRLGDST IEYAPDFRFY ITTKLRNPHY LPETSVKVTL LNFMITPEGM QDQLLGIVVA QERPDLEEEK QALILQGAEN KRQLKEIEDK ILEVLSSSEG NILEDETAIK ILSSSKALAN EISQKQEVAE ETEKKIDTTR MGYRPIAIHS SILFFSLADL ANIEPMYQYS LTWFINLFIL SIENSEKSEI LAKRLQILKD HFTYSLYVNV CRSLFEKDKL LFSFCLTINL LLHERAINKA EWRFLLTGGI GLDNPYANLC TWLPQKSWDE ICRLDDLPAF KTIRREFMRL KDGWKKVYDS LEPHHEVFPE EWEDKANEFQ RMLIIRCLRP DKVIPMLQEF IINRLGRAFI EPPPFDLAKA FGDSNCCAPL IFVLSPGADP MAALLKFADD QGYGGSKLSS LSLGQGQGPI AMKMLEKAVK EGTWVVLQNC HLATSWMPTL EKVCEELSPE STHPDFRMWL TSYPSPNFPV SVLQNGVKMT NEAPKGLRAN IIRSYLMDPI SDPEFFGSCK KPEEFKKLLY GLCFFHALVQ ERRKFGPLGW NIPYEFNETD LRISVQQLHM FLNQYEELPY EALRYMTGEC NYGGRVTDDW DRRTLRSILN KFFNPELVEN SDYKFDSSGI YFVPPSGDHK SYIEYTKTLP LTPAPEIFGM NANADITKDQ SETQLLFDNI LLTQSRSAGA GAKSSDEVVN EVASDILGKL PNNFDIEAAM RRYPTTYTQS MNTVLVQEMG RFNKLLKTIR DSCVNIQKAI KGLAVMSTDL EEVVSSILNV KIPEMWMGKS YPSLKPLGSY VNDFLARLKF LQQWYEVGPP PVFWLSGFFF TQAFLTGAQQ NYARKYTIPI DLLGFDYEVM EDKEYKHPPE DGVFIHGLFL DGASWNRKIK KLAESHPKIL YDTVPVMWLK PCKRADIPKR PSYVAPLYKT SERRGVLSTT GHSTNFVIAM TLPSDQPKEH WIGRGVALLC QLNS
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
Which diseases are associated with DNAH7?
The strongest Open Targets associations for DNAH7 are primary ciliary dyskinesia, Abnormal muscle tone, Abnormal basal ganglia morphology, basal ganglia disease and Seizure.
How long is the DNAH7 protein?
The Homo sapiens DNAH7 protein (UniProt Q8WXX0) is 4024 amino acids long.
Browse: Targets: D · all protein targets A–Z · drugs A–Z.
Sources
- UniProtKB Q8WXX0 — name, gene, function, sequence, keywords (CC BY 4.0)
- AlphaFold DB Q8WXX0 — predicted 3D structure (CC BY 4.0)
- Open Targets Platform — disease associations and tractability (CC0)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.